Bruker Announces Closing of Acquisitions of Roentec and PGT Microanalysis Business
Complete the form below to unlock access to ALL audio articles.
Bruker AXS Inc. has announced the closing of two complementary acquisitions in the $150 million per annum X-ray microanalysis market.
Applications of microanalysis include nanotechnology and advanced materials research, as well as materials analysis and quality control, with customers in many industries, academia and government research facilities.
On October 14th and 26th, 2005, Bruker AXS had announced agreements for the acquisition of Roentec AG and the microanalysis business of Princeton Gamma-Tech (PGT) Instruments, Inc., respectively.
Following the completion of the two closings in the last two business days, Bruker AXS has now combined the two units into a newly created 'Bruker AXS Microanalysis' business, under the responsibility of Bruker AXS Executive Vice President Roger Durst, with operations in Berlin (Germany), Coventry (UK), as well as Madison, WI and the Princeton, NJ area in the United States.
Bruker AXS also has integrated the management teams of both microanalysis units, and announces the appointment of Mr. Thomas Schuelein, previously with Roentec, as Vice President for Microanalysis.
Mr. Douglas Skinner, previously with PGT, has been appointed as Assistant Vice President for Microanalysis.
Frank Laukien, President and CEO of Bruker BioSciences, stated, "We are excited to welcome both of these outstanding teams to Bruker AXS."
"The strong synergies between Roentec and the PGT microanalysis business, in combination with our proprietary X-ray technologies and our global sales and support infrastructure, will make the new Bruker AXS Microanalysis business stronger than the sum of its parts."
"Moreover, our worldwide distribution capabilities can also enhance the revenue growth for the novel transportable microXRF and TXRF systems that have been pioneered by Roentec."
"Overall, we believe that this acquisition increases the accessible market for Bruker BioSciences, that it will further accelerate our growth and profitability, and that for our shareholders it will be accretive to cash EPS already in 2006."
